Gestational GLP-1s Tied to Adverse Obstetric Outcomes
A study has found that mothers with overweight or obesity who used semaglutide during pregnancy faced higher risks of adverse outcomes. These include excessive gestational weight gain, gestational diabetes, and cesarean delivery. The findings highlight the need for further research on the implications of GLP-1 use in pregnancy and its effects on long-term child health.
- ▪Mothers exposed to semaglutide had a 5.12-kg greater gestational weight gain compared to nonusers.
- ▪The study reported higher risks for gestational diabetes and excessive fetal growth among semaglutide users.
- ▪About a third of women on semaglutide before pregnancy continued its use after conception.
Opening excerpt (first ~120 words) tap to expand
Mothers with overweight or obesity exposed to semaglutide before and during pregnancy had higher risks for excessive gestational weight gain, gestational diabetes, excessive fetal growth, and cesarean delivery than nonusers, a national database study in Obstetrics and Gynecology found.Yang Yu, PhD, MPH, MNSStudy investigators led by Yang Yu, PhD, MPH, MNS, an assistant professor at the University of Rochester School of Nursing in Rochester, New York, noted that current drug labeling advises discontinuing the drug at least 2 months before attempting to conceive, a warning based on animal research linking use in pregnancy to miscarriage, impaired fetal growth, and congenital anomalies.However, unintended exposure during pregnancy is likely common, given the growth of GLP-1 use in…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
